Get the Stockscreener App
12.34
0.65%
0.08
After Hours:
12.35
0.010
+0.08%
Mbx Biosciences Inc stock is traded at $12.34, with a volume of 564.16K.
It is up +0.65% in the last 24 hours and down -15.48% over the past month.
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$12.26
Open:
$12.21
24h Volume:
564.16K
Relative Volume:
2.29
Market Cap:
$425.28M
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-7.8835
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
+23.28%
1M Performance:
-15.48%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.00
$13.43
1-Week Range:
$9.57
$14.23
52-Week Range:
$9.424
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
12406 HORESHAM STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
12.34 | 425.28M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
Mbx Biosciences Inc Stock (MBX) Latest News
The Future of MBX Biosciences Inc: Analyzing MBX - The InvestChronicle
P. Kent Hawryluk Acquires 50,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock - MarketBeat
MBX Biosciences Director Makes Bold Stock Move - TipRanks
MBX Biosciences to Participate in Upcoming February Investor Conferences - The Manila Times
MBX Biosciences CEO to Present at Three Major Healthcare Investor Conferences in February - StockTitan
16,400 Shares in MBX Biosciences, Inc. (NYSE:MBX) Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Invests $579,000 in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Long-acting MBX 2109 may offer more convenient symptom relief - Hypoparathyroidism News
Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia - Yahoo Finance
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action - AOL
MBX Biosciences (NYSE:MBX) Shares Gap DownTime to Sell? - MarketBeat
MBX 1416 shows promise in Phase 1 trial for hypoglycemia treatment - Investing.com India
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia - The Manila Times
MBX Biosciences Announces Positive Phase 1 Topline Results - GlobeNewswire
MBX Biosciences' Long-Acting GLP-1 Drug Shows Promise in Phase 1 Trial with Weekly Dosing - StockTitan
Barclays PLC Buys Shares of 16,400 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Jane Street Group LLC Makes New $690,000 Investment in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Trading Down 6.6%Time to Sell? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Biotech IPO Shares 2025 Climb In Trading Debuts After Deals Upsized - Browvopetshop
MBX Biosciences (NYSE:MBX) Stock Price Down 7.3%Time to Sell? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Gap Down – Should You Sell? - Defense World
Franklin Resources Inc. Invests $11.69 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Teachers Retirement System of The State of Kentucky Makes New $694,000 Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
MBX Biosciences (NYSE:MBX) Trading 4.6% HigherHere's Why - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Gap UpWhat's Next? - MarketBeat
The Manufacturers Life Insurance Company Invests $1.20 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Wellington Management Group LLP Takes $74.26 Million Position in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Frazier Life Sciences Management L.P. Makes New $155.50 Million Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Maven Securities LTD Makes New $1.30 Million Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
RA Capital Management L.P. Takes $39.26 Million Position in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism - The Manila Times
MBX Biosciences Announces MBX 2109 Phase 1 Study Results - GlobeNewswire
NEA Management Company LLC Invests $93.90 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Down 3.6% – Should You Sell? - Defense World
MBX Biosciences (NYSE:MBX) Shares Down 3.6%Time to Sell? - MarketBeat
MBX Biosciences (NYSE:MBX) Trading Up 6.5%Still a Buy? - MarketBeat
MBX Biosciences completes phase 1 trial of diabetes drug By Investing.com - Investing.com Canada
MBX Biosciences completes phase 1 trial of diabetes drug - Investing.com India
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mbx Biosciences Inc Stock (MBX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mathers Edward T | Director |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| BASKETT FOREST | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Behbahani Ali | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Chang Carmen | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Florence Anthony A. Jr. | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Makhzoumi Mohamad | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Walker Paul Edward | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| Yang Rick | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| SANDELL SCOTT D | 10% Owner |
Sep 16 '24 |
Buy |
16.00 |
500,000 |
8,000,000 |
3,614,486 |
| ORBIMED ADVISORS LLC | Director |
Sep 16 '24 |
Buy |
16.00 |
750,000 |
12,000,000 |
3,158,428 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):